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In the course of vascular development, sprouting is one of the key processes to 
drive new vessel formation. Vascular sprouting is a dynamic process. Stimulation of 
vascular engothelial growth fator (VEGF) is required in this process, and other 
signalling pathways such as Agiopoitins / Ties also involved in the controlling of the 
process.  However, the detail molecular mechanisms that regulate this critical 
biological process remain unclear for many aspects.  Particularly, little is known about 
such process during the lymphatic development. Neuropilins are a small family of 
transmembrane receptor (two members in mammalians). In present study, we show 
that Neuropilin 2 (Nrp2), a transmembrane receptor for class 3 semaphorins and some 
VEGF family members, including the lymphangiogenic growth factor VEGF-C, plays 
an important role in lymphatic sprouting. We demonstrate that blocking of VEGF-C 
binding to Nrp2 using a monoclonal antibody specifically blocks sprouting of 
developing lymphatic endothelial tip cells in vivo. Blocking VEGF-C binding to Nrp2 
in vitro shows that Nrp2 plays a selective role in driving sprout formation by 
modulating lymphatic endothelial tip-cell extension and preventing tip-cell stalling 
and retraction. Genetic deletion of Nrp2 reproduces the sprouting defects seen after 
antibody treatment. Therefore, Nrp2 is indispensable regulator for lymphatic sprouting. 
To date, no evedent for Nrps to mediate signal transduction alone, their actions on 
cells are achieved mainly via the canonical receptors for Semaphorin (plexin) and for 
VEGF (VEGFR). In the vascular system, Nrp1 has been fund to corporate with 
VEGFR2 during angiogenesis; While Nrp2 found in vitro to interact with both 
VEGFR2 and VEGFR3 for signaling. To investigate if this defect depends on Nrp2 
interaction with VEGFR2 and/or VEGFR3, we intercrossed heterozygous mice 
lacking one allele of these receptors. Nrp2Vegfr2 double heterozygous mice developed 
normally without detectable lymphatic sprouting defects. In contrast, Nrp2Vegfr3 
double heterozygotes showed a reduction of lymphatic vessel sprouting, lymphatic 
hyperplasia and decreased lymph vessel branching in all of  organs. Futhermore, Nrp2-
/-Vegfr3+/- mice enhanced the defects found in double heterozygotes, with a severe 
edema developed. In a summary, our study demonstrated that the interaction between 
Nrp2 and VEGFR3 mediates proper lymphatic vessel sprouting in response to VEGF-
C 
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Figue 1-1，Schematic illustration of blood and lymphatic systerm 
（Cueni et al. Journal of Investigative Dermatology 2006, 126, 2167-2177） 
 









新生（angiogenesis）[2]。 血管发生与血管新生的过程图 1-2 所示[3]：中胚层的
祖细胞（mesodermal precursor），在主要在来自内胚层的成纤维生长因子
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